Analysts have been eager to weigh in on the Healthcare sector with new ratings on Actinium Pharmaceuticals (NYSE:ATNM) and Vascular Biogenics (NASDAQ:VBLT).
Actinium Pharmaceuticals (ATNM)
In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $6. The company’s shares closed yesterday at $0.66.
Marango said:
“We like how strategic and forward-looking Actinium has been recently with its pipeline programs. (anti-CD45+isotope) is cooking (25% enrolled), Actinium continues to diversify the clinical program of Actimab-A (anti-CD33+isotope). The newest protocol in MRD+ AML announced recently is now the fifth trial across three indications, which include AML, MDS, and MM.”
According to TipRanks.com, Marango is a 4-star analyst with an average return of 31.1% and a 50.0% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Aptevo Therapeutics Inc.
Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $3.58, representing a 442.4% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
.
See today’s analyst top recommended stocks >>
Vascular Biogenics (VBLT)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Hold rating on Vascular Biogenics today and set a price target of $3. The company’s shares closed yesterday at $2.15, close to its 52-week low of $2.00.
Ramakanth wrote:
“We maintain our Neutral rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying an 6x multiple to our 2026 sales estimate discounted at 18%; and (2) price-earnings multiple analysis applying an 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.4% and a 40.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Vascular Biogenics with a $3 average price target, which is a 39.5% upside from current levels. In a report released yesterday, Chardan Capital also downgraded the stock to Hold with a $3 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
